ALLMedicine™ Juvenile Myelomonocytic Leukemia Center
Research & Reviews 453 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045514
Blood Advances; Spitzer B, Dela Cruz FS et. al.
Apr 1st, 2021 - Myeloid/lymphoid neoplasm with eosinophilia (MLN-Eo) is a World Health Organization (WHO) established category of hematologic malignancies primarily arising in adults. We discuss an 8-month-old infant who presented with clinical features similar t...
https://doi.org/10.1097/MPH.0000000000002149
Journal of Pediatric Hematology/oncology; Mariani RA, Jennings L et. al.
Mar 26th, 2021 - The diagnostic criteria for juvenile myelomonocytic leukemia have recently been revised to include clinical findings and RAS-pathway gene mutations per the 2016 World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissu...
https://doi.org/10.1007/s11899-021-00622-8 10.1182/blood-2016-03-643544 10.1038/leu.2014.125 10.1002/ajh.25684 10.1182/blood-2005-10-4149 10.1038/bcj.2017.41 10.1182/blood-2014-10-607341 10.1038/leu.2011.10 10.1038/s41375-019-0690-7 10.1200/JCO.2012.47.3314 10.1182/blood-2016-05-714030 10.1038/s41375-020-0889-7 10.1002/cncr.21792 10.1200/JCO.2002.04.117 10.1182/blood-2020-139901 10.1182/blood-2020-142469 10.1182/blood-2020-138680 10.1038/ncomms10767 10.1016/0006-2952(65)90175-9 10.1182/blood-2019-122980 10.1200/JCO.2010.34.4226 10.1038/leu.2015.265 10.1038/leu.2008.145 10.1002/ajh.25216 10.1182/blood-2020-136385 10.1182/blood-2020-140644 10.1158/2159-8290.CD-19-0710 10.1158/1078-0432.CCR-15-2781 10.1002/ajh.24972 10.1182/blood.V126.23.1658.1658 10.1200/JCO.2017.73.4418 10.1016/j.clml.2018.12.005 10.1016/S1470-2045(15)00038-8 10.1016/S2352-3026(19)30029-8 10.1038/s41375-019-0447-3 10.1080/10428194.2016.1243681 10.1080/2162402X.2020.1777625 10.1182/bloodadvances.2020002415 10.1038/s41598-017-12940-0 10.1182/blood-2012-10-460170 10.1182/blood.2019004352 10.1002/ajh.23373 10.1182/blood-2019-123854 10.1158/1078-0432.CCR-13-0485 10.1007/s12185-020-02994-8 10.1158/1078-0432.CCR-20-2586 10.1016/S2152-2650(20)30981-2 10.1080/17474086.2018.1421937 10.1182/hematology.2020000163 10.1038/ng.3400 10.1007/BF00443016 10.1182/blood-2006-09-046649 10.1080/08880018.2020.1767244 10.1002/pbc.21038 10.1182/blood-2004-05-1944 10.1182/blood-2014-08-550483 10.1002/pbc.27034 10.1016/j.semcancer.2017.10.011 10.1200/JCO.2019.37.15_suppl.10031 10.1182/blood-2015-01-619734 10.1002/pbc.27948 10.1182/blood-2008-12-195693 10.1002/pbc.27905 10.3389/fonc.2020.00484 10.1097/MD.0000000000023606 10.1182/blood-2018-99-114777 10.1111/petr.13423 10.1002/pbc.27284 10.1182/blood.V128.22.4805.4805 10.1158/1078-0432.CCR-20-3184 10.1111/bjh.13915 10.1016/j.blre.2020.100652 10.1038/s41375-018-0169-y
Current Hematologic Malignancy Reports; McCullough KB, Kuhn AK et. al.
Mar 17th, 2021 - For decades, the management of chronic myelomonocytic leukemia (CMML) or juvenile myelomonocytic leukemia (JMML) has been largely inextricable from myelodysplastic syndromes (MDS), myeloproliferative neoplasms, and acute myeloid leukemia. Hallmark...
https://doi.org/10.1007/s11899-021-00611-x 10.1016/j.leukres.2008.08.022 10.1038/ng.3400 10.1182/blood-2004-05-1944 10.1007/s12185-014-1715-7 10.1182/blood-2013-03-491589 10.1200/JCO.1997.15.2.566 10.3389/fimmu.2014.00491 10.1182/blood.V91.1.365 10.1182/blood.V61.6.1098.1098 10.1097/00043426-199023000-00007 10.1097/00043426-200202000-00016 10.1002/pbc.24359 10.1097/MPH.0b013e31819ed260 10.1182/blood-2014-11-567917 10.1016/j.jpeds.2015.04.064 10.1093/tropej/48.4.200 10.1182/blood-2018-11-844688 10.1038/leu.2010.18 10.1182/blood-2017-07-798157 10.1073/pnas.150079597 10.1007/s12185-018-2522-3 10.1038/leu.2016.250 10.1002/pbc.24148 10.1016/j.beha.2020.101171 10.1111/ijlh.12776 10.1182/blood-2016-03-643544 10.1097/MPH.0b013e3182055e44 10.1111/j.1346-8138.2008.00486.x 10.1097/MPH.0b013e318159a4fb 10.1182/blood.V85.7.1742.bloodjournal8571742 10.1002/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q 10.1136/bmj.1.5845.71 10.1002/ajmg.a.35290 10.4274/tjh.2017.0021 10.1038/ng.3420 10.1002/humu.23399 10.1038/leu.2015.85 10.1182/blood-2010-08-298968 10.1371/journal.pone.0145394 10.1038/s41467-017-02177-w 10.1182/blood-2014-08-550483 10.1203/PDR.0b013e3181961d2a 10.1038/ng1156 10.1182/blood-2003-09-3287 10.1016/j.semcdb.2016.06.006 10.1182/blood-2010-01-265652 10.1038/leu.2016.326 10.1128/MCB.01330-08 10.1016/j.celrep.2015.09.019 10.1038/cdd.2013.145 10.1371/journal.pgen.1006259 10.1016/j.beem.2010.09.002 10.3324/haematol.2014.114595 10.1182/blood-2005-02-0531 10.1080/10245330512331390078 10.1111/j.1365-2141.2010.08525.x 10.1002/ajmg.c.30300 10.1016/S0140-6736(03)13266-7 10.1038/ng.641 10.1136/jmg.2010.076836 10.1182/blood-2009-01-198416 10.1002/pbc.25271 10.1136/jmedgenet-2016-104432 10.1101/gad.297135.117 10.3324/haematol.2009.016865 10.1101/cshperspect.a002279 10.1016/j.blre.2020.100652 10.1038/sj.leu.2401240 10.1111/j.1365-2141.2009.07894.x 10.1002/ajmg.a.35513 10.1182/blood-2012-02-406090 10.1182/asheducation-2018.1.307 10.1038/s41375-018-0343-2 10.1182/blood-2010-07-295501 10.1182/blood-2010-08-301515 10.1111/ced.13668 10.1073/pnas.0702975104 10.1182/blood-2014-01-548958 10.1111/cei.12986 10.1007/s10875-015-0163-3 10.1182/blood-2014-09-601690 10.1182/blood-2006-09-046649 10.1182/blood-2007-09-111831 10.1038/leu.2013.82 10.1093/hmg/ddu148 10.1016/0092-8674(90)90151-4 10.1001/archderm.1995.01690200040007 10.1038/ng.2698 10.1038/s41467-017-02178-9 10.1111/j.1399-3046.2008.00931.x 10.1038/sj.leu.2402407 10.1046/j.0007-1048.2001.03333.x 10.3389/fped.2014.00025 10.1038/sj.bmt.1704438 10.1016/j.beha.2010.06.005 10.1111/j.1365-2141.2009.07783.x 10.1002/pbc.21038 10.1182/blood.V86.2.825.bloodjournal862825 10.1038/bmt.2014.3 10.1002/pbc.24702 10.1016/j.bbmt.2013.04.015 10.1200/JCO.2009.24.4426 10.1182/blood-2015-01-619734 10.1182/blood-2008-12-195693 10.1016/j.semcancer.2017.10.011 10.1111/bjh.14876 10.1200/JCO.2019.37.15_suppl.10031 10.1002/ajmg.a.34439 10.1038/leu.2016.14 10.1182/blood-2013-10-535104 10.18632/oncotarget.21455 10.1111/j.1365-2141.2010.08393.x 10.1186/s13148-016-0216-3 10.1002/pbc.27034 10.3324/haematol.2015.136002 10.1111/j.1365-2141.2011.08817.x 10.1172/JCI63193 10.1126/scitranslmed.3001069
Current Hematologic Malignancy Reports; Greenmyer JR, Kohorst M
Feb 25th, 2021 - Juvenile myelomonocytic leukemia (JMML) is a rare but severe pediatric neoplasm with hematopoietic stem cell transplant as its only established curative option. The development of targeted therapeutics for JMML is being guided by an understanding ...
https://doi.org/10.1016/j.clp.2020.11.002
Clinics in Perinatology; Brown PA
Feb 15th, 2021 - Neonates are at risk for 3 major forms of leukemia in the first year of life: acute leukemia, juvenile myelomonocytic leukemia, and transient abnormal myelopoiesis associated with Down syndrome. These disorders are rare but generate interest due t...
Clinicaltrials.gov 459 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045514
Blood Advances; Spitzer B, Dela Cruz FS et. al.
Apr 1st, 2021 - Myeloid/lymphoid neoplasm with eosinophilia (MLN-Eo) is a World Health Organization (WHO) established category of hematologic malignancies primarily arising in adults. We discuss an 8-month-old infant who presented with clinical features similar t...
https://doi.org/10.1097/MPH.0000000000002149
Journal of Pediatric Hematology/oncology; Mariani RA, Jennings L et. al.
Mar 26th, 2021 - The diagnostic criteria for juvenile myelomonocytic leukemia have recently been revised to include clinical findings and RAS-pathway gene mutations per the 2016 World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissu...
https://doi.org/10.1007/s11899-021-00622-8 10.1182/blood-2016-03-643544 10.1038/leu.2014.125 10.1002/ajh.25684 10.1182/blood-2005-10-4149 10.1038/bcj.2017.41 10.1182/blood-2014-10-607341 10.1038/leu.2011.10 10.1038/s41375-019-0690-7 10.1200/JCO.2012.47.3314 10.1182/blood-2016-05-714030 10.1038/s41375-020-0889-7 10.1002/cncr.21792 10.1200/JCO.2002.04.117 10.1182/blood-2020-139901 10.1182/blood-2020-142469 10.1182/blood-2020-138680 10.1038/ncomms10767 10.1016/0006-2952(65)90175-9 10.1182/blood-2019-122980 10.1200/JCO.2010.34.4226 10.1038/leu.2015.265 10.1038/leu.2008.145 10.1002/ajh.25216 10.1182/blood-2020-136385 10.1182/blood-2020-140644 10.1158/2159-8290.CD-19-0710 10.1158/1078-0432.CCR-15-2781 10.1002/ajh.24972 10.1182/blood.V126.23.1658.1658 10.1200/JCO.2017.73.4418 10.1016/j.clml.2018.12.005 10.1016/S1470-2045(15)00038-8 10.1016/S2352-3026(19)30029-8 10.1038/s41375-019-0447-3 10.1080/10428194.2016.1243681 10.1080/2162402X.2020.1777625 10.1182/bloodadvances.2020002415 10.1038/s41598-017-12940-0 10.1182/blood-2012-10-460170 10.1182/blood.2019004352 10.1002/ajh.23373 10.1182/blood-2019-123854 10.1158/1078-0432.CCR-13-0485 10.1007/s12185-020-02994-8 10.1158/1078-0432.CCR-20-2586 10.1016/S2152-2650(20)30981-2 10.1080/17474086.2018.1421937 10.1182/hematology.2020000163 10.1038/ng.3400 10.1007/BF00443016 10.1182/blood-2006-09-046649 10.1080/08880018.2020.1767244 10.1002/pbc.21038 10.1182/blood-2004-05-1944 10.1182/blood-2014-08-550483 10.1002/pbc.27034 10.1016/j.semcancer.2017.10.011 10.1200/JCO.2019.37.15_suppl.10031 10.1182/blood-2015-01-619734 10.1002/pbc.27948 10.1182/blood-2008-12-195693 10.1002/pbc.27905 10.3389/fonc.2020.00484 10.1097/MD.0000000000023606 10.1182/blood-2018-99-114777 10.1111/petr.13423 10.1002/pbc.27284 10.1182/blood.V128.22.4805.4805 10.1158/1078-0432.CCR-20-3184 10.1111/bjh.13915 10.1016/j.blre.2020.100652 10.1038/s41375-018-0169-y
Current Hematologic Malignancy Reports; McCullough KB, Kuhn AK et. al.
Mar 17th, 2021 - For decades, the management of chronic myelomonocytic leukemia (CMML) or juvenile myelomonocytic leukemia (JMML) has been largely inextricable from myelodysplastic syndromes (MDS), myeloproliferative neoplasms, and acute myeloid leukemia. Hallmark...
https://doi.org/10.1007/s11899-021-00611-x 10.1016/j.leukres.2008.08.022 10.1038/ng.3400 10.1182/blood-2004-05-1944 10.1007/s12185-014-1715-7 10.1182/blood-2013-03-491589 10.1200/JCO.1997.15.2.566 10.3389/fimmu.2014.00491 10.1182/blood.V91.1.365 10.1182/blood.V61.6.1098.1098 10.1097/00043426-199023000-00007 10.1097/00043426-200202000-00016 10.1002/pbc.24359 10.1097/MPH.0b013e31819ed260 10.1182/blood-2014-11-567917 10.1016/j.jpeds.2015.04.064 10.1093/tropej/48.4.200 10.1182/blood-2018-11-844688 10.1038/leu.2010.18 10.1182/blood-2017-07-798157 10.1073/pnas.150079597 10.1007/s12185-018-2522-3 10.1038/leu.2016.250 10.1002/pbc.24148 10.1016/j.beha.2020.101171 10.1111/ijlh.12776 10.1182/blood-2016-03-643544 10.1097/MPH.0b013e3182055e44 10.1111/j.1346-8138.2008.00486.x 10.1097/MPH.0b013e318159a4fb 10.1182/blood.V85.7.1742.bloodjournal8571742 10.1002/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q 10.1136/bmj.1.5845.71 10.1002/ajmg.a.35290 10.4274/tjh.2017.0021 10.1038/ng.3420 10.1002/humu.23399 10.1038/leu.2015.85 10.1182/blood-2010-08-298968 10.1371/journal.pone.0145394 10.1038/s41467-017-02177-w 10.1182/blood-2014-08-550483 10.1203/PDR.0b013e3181961d2a 10.1038/ng1156 10.1182/blood-2003-09-3287 10.1016/j.semcdb.2016.06.006 10.1182/blood-2010-01-265652 10.1038/leu.2016.326 10.1128/MCB.01330-08 10.1016/j.celrep.2015.09.019 10.1038/cdd.2013.145 10.1371/journal.pgen.1006259 10.1016/j.beem.2010.09.002 10.3324/haematol.2014.114595 10.1182/blood-2005-02-0531 10.1080/10245330512331390078 10.1111/j.1365-2141.2010.08525.x 10.1002/ajmg.c.30300 10.1016/S0140-6736(03)13266-7 10.1038/ng.641 10.1136/jmg.2010.076836 10.1182/blood-2009-01-198416 10.1002/pbc.25271 10.1136/jmedgenet-2016-104432 10.1101/gad.297135.117 10.3324/haematol.2009.016865 10.1101/cshperspect.a002279 10.1016/j.blre.2020.100652 10.1038/sj.leu.2401240 10.1111/j.1365-2141.2009.07894.x 10.1002/ajmg.a.35513 10.1182/blood-2012-02-406090 10.1182/asheducation-2018.1.307 10.1038/s41375-018-0343-2 10.1182/blood-2010-07-295501 10.1182/blood-2010-08-301515 10.1111/ced.13668 10.1073/pnas.0702975104 10.1182/blood-2014-01-548958 10.1111/cei.12986 10.1007/s10875-015-0163-3 10.1182/blood-2014-09-601690 10.1182/blood-2006-09-046649 10.1182/blood-2007-09-111831 10.1038/leu.2013.82 10.1093/hmg/ddu148 10.1016/0092-8674(90)90151-4 10.1001/archderm.1995.01690200040007 10.1038/ng.2698 10.1038/s41467-017-02178-9 10.1111/j.1399-3046.2008.00931.x 10.1038/sj.leu.2402407 10.1046/j.0007-1048.2001.03333.x 10.3389/fped.2014.00025 10.1038/sj.bmt.1704438 10.1016/j.beha.2010.06.005 10.1111/j.1365-2141.2009.07783.x 10.1002/pbc.21038 10.1182/blood.V86.2.825.bloodjournal862825 10.1038/bmt.2014.3 10.1002/pbc.24702 10.1016/j.bbmt.2013.04.015 10.1200/JCO.2009.24.4426 10.1182/blood-2015-01-619734 10.1182/blood-2008-12-195693 10.1016/j.semcancer.2017.10.011 10.1111/bjh.14876 10.1200/JCO.2019.37.15_suppl.10031 10.1002/ajmg.a.34439 10.1038/leu.2016.14 10.1182/blood-2013-10-535104 10.18632/oncotarget.21455 10.1111/j.1365-2141.2010.08393.x 10.1186/s13148-016-0216-3 10.1002/pbc.27034 10.3324/haematol.2015.136002 10.1111/j.1365-2141.2011.08817.x 10.1172/JCI63193 10.1126/scitranslmed.3001069
Current Hematologic Malignancy Reports; Greenmyer JR, Kohorst M
Feb 25th, 2021 - Juvenile myelomonocytic leukemia (JMML) is a rare but severe pediatric neoplasm with hematopoietic stem cell transplant as its only established curative option. The development of targeted therapeutics for JMML is being guided by an understanding ...
https://doi.org/10.1016/j.clp.2020.11.002
Clinics in Perinatology; Brown PA
Feb 15th, 2021 - Neonates are at risk for 3 major forms of leukemia in the first year of life: acute leukemia, juvenile myelomonocytic leukemia, and transient abnormal myelopoiesis associated with Down syndrome. These disorders are rare but generate interest due t...
News 9 results
https://www.mdedge.com/hematology-oncology/article/184841/leukemia-myelodysplasia-transplantation/study-suggests-dasatinib-could-treat
HT Staff
Jul 18th, 2018 - © Universitätsklinikum Freiburg Micrograph showing JMML New research suggests dasatinib could treat certain patients with juvenile myelomonocytic leukemia (JMML) or acute myeloid leukemia (AML). The study showed that TNK2 inhibition has a negative.
https://www.mdedge.com/hematology-oncology/article/185191/cythemias/dna-methylation-may-predict-outcomes-jmml
HT Staff
Jan 11th, 2018 - General Medical Sciences DNA helices Image courtesy of the National Institute of New research suggests DNA methylation may be used to predict how children with juvenile myelomonocytic leukemia (JMML) will respond to treatment. Researchers found th.
https://www.mdedge.com/hematology-oncology/article/187540/leukemia-myelodysplasia-transplantation/study-provides-clearer-picture-jmml
HT Staff
Oct 20th, 2015 - Smiling baby Photo by Petr Kratochvil Whole-exome sequencing has provided new insights that may lead to better treatment of juvenile myelomonocytic leukemia (JMML), according to researchers. The group identified new mutations that appear to drive.
https://www.mdedge.com/hematology-oncology/article/187565/leukemia-myelodysplasia-transplantation/findings-may-inform-design-new
HT Staff
Oct 9th, 2015 - Colony of iPSCs Image from the Salk Institute Researchers have used induced pluripotent stem cells (iPSCs) to model juvenile myelomonocytic leukemia (JMML) and gain new insight into the disease. The team noted that somatic PTPN11 mutations are kno.
https://www.mdedge.com/hematology-oncology/article/187749/leukemia-myelodysplasia-transplantation/improved-hsct-outcomes-due
HT Staff
Jul 28th, 2015 - Cord blood for transplant Photo courtesy of NHS Investigators have reported favorable results of allogeneic hematopoietic stem cell transplant (HSCT) in a small study of patients with juvenile myelomonocytic leukemia (JMML). The team said the posi.
